Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

References

• Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with Factor VIII and IX inhibitors. Haemostasis 1996;26(Suppl 1):124–30
   PubMedGoogle Scholar
• FEIBA® VH Anti-Inhibitor Coagulant Complex, vapor heated, product information. Revised May 2004. Baxter Healthcare Corporation, Westlake Village, CA. Available at http://www. baxter.com/products/biopharmaceuticals/hemophilia/sub/feiba_ vh html [last accessed 28 June 2005]
   Google Scholar
• NovoSeven® product information. Novo Nordisk Inc, Princeton, New Jersey. Available at http://www.us.novoseven.com/content/ us_vers/us_novoseven.asp [last accessed 28 June 2005]
   Google Scholar
• Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542–7
   PubMed Web of Science ®Google Scholar
• Monroe DM, Hoffman M, Oliver JA, et al. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S15–S20
   Google Scholar
• Brackmann HH, Effenberger E, Hess L, et al. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000;11(Suppl 1):S39–S44
   Google Scholar
• Lacey L. Economic impact of treating inhibitor patients. Pathophysiol Haemost Thromb 2002;32(Suppl 1):29–32
   PubMedGoogle Scholar
• Aldecort L (meeting chair). Meeting report. Economic aspects of haemophilia care. Haemophilia 1999;5:216–9
   PubMedGoogle Scholar
• Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999;5:397–401
   PubMed Web of Science ®Google Scholar
• Knight C, Paisley S, Wight J, et al. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003;9:521–40
   PubMed Web of Science ®Google Scholar
• Laurian Y, Goudemand J, Negrier C, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII and factor IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998;9 (Suppl 1):S155–S156
   Google Scholar
• Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80(6):912–8
   PubMed Web of Science ®Google Scholar
• Ingerslev J, Thykjaer H, Schiebel E. Approaches towards successful home treatments in patients with inhibitors. Eur J Haematol Suppl 1998;63:11–4
   Google Scholar
• Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients [FEIBA Study Group]. Transfusion 1990;30:626–30
   PubMed Web of Science ®Google Scholar
• Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997;77:1113–9
   PubMed Web of Science ®Google Scholar
• Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 1999;28:1–9
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Growth chart 2 to 20 years: boys. Stature-for-age and weight-for-age percentiles. Centers for Disease Control and Prevention, May 30, 2000. Available at http://www.cdc.gov/growthcharts [last accessed 14 July 2005]
   Google Scholar
• Anon. Drug topics redbook updates. Montvale, New Jersey: Thomson Medical Economics, Inc.; August, 2005
   Google Scholar
• Rahim MT, Milbrandt EB, Dremsizov TT, et al. Pricing critical care: an updated Russell equation. Presented at the Society of Critical Care Medicine, 33rd Critical Care Congress, Orlando, FL – February 20–25, 2004
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479–500
   PubMed Web of Science ®Google Scholar
• Ekert H, Brewin T, Boey W, et al. Cost-utility of recombinant factor VIIa (NovoSeven®) in six children with long-standing inhibitors to factors VIII and IX. Haemophilia 2001;7:279–85
   PubMed Web of Science ®Google Scholar
• Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002;5:119–33
   Google Scholar
• Dundar S, Zulfikar B, Kavakli K, et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005;8:45–54
   Google Scholar
• Berger A, Edelsberg J, Neufeld E, et al. Cost-effectiveness of FEIBA VH vs. rFVIIa as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors. Poster presentation at the Hemophilia 2004 World Congress, October 17–21, 2004, Bangkok, Thailand [abstract No. 114E]
   Google Scholar
• Putnam KG, Bohn RL, Ewenstein BM, et al. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005;11:261–9
   PubMed Web of Science ®Google Scholar
• Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J Manag Care Pharm 2005;11(Suppl 4):S7–S10
   Google Scholar